India Biogeneric.........for double digit dollar revenue

One of the largest generic manufacturer of India Inc Cipla is planning to launch its own line of Bio similar products, in a press release Cipla's chairman Yusuf Hamied said that he plans to invest in companies in India and Hong Kong who will be able to produce so-called monoclonal antibodies. The technology will enable Mumbai-based Cipla to have access to products modelled bio equivalence to Roche’s Avastin, Herceptin cancer drugs and Amgen’s rheumatoid arthritis treatment Enbrel.

PS: Cipla is the largest supplier of HIV drugs:)

Link:http://www.businessweek.com/news/2010-06-16/cipla-targets-19-billion-a-year-roche-amgen-drugs-update2-.html

Europe's Big Daddies for Active M&A

Last year after the present Sanofi's new CEO joined the board from GSK, Sanofi has been aggressively into Mergers and Acquisitions, now another big giant to look for is Bayer for long time Bayer has been into active patent portfolio management and out licensing but as we have new CEO on board we have many mergers and acquisition awaiting from Bayer's end.
....................................................................................
Yesterday I was reading some analyst report in which they have mentioned about some companies for which venture capitalists have high hopes, they include the following

-RXi Pharmaceuticals Corporation (Nasdaq: RXII): RXi's proprietary sd-rxRNA molecules has a unique 'self delivery' property.
-Northwest Bio therapeutics (OTC BB: NWBO.OB): Northwest Bio therapeutics' vaccine to combat brain cancer
-Dendreon Corporation's (NASDAQ: DNDN): Dendreon announced recently that their drug Provenge for treatment for prostate cancer has been approved by FDA.

Sanofi deal Update -2010-Q2

In my last article I had mentioned about Sanofi Aventis generic market penetration in emerging markets, today morning the news was that Sanofi is interested in venturing into Ophthalmology domain and in the news it was also mentioned that last year as it had closed 33 deals it is going to close the same number of deals by this year end......An interesting observation is that last year Abbott was the company which had invested heavily in Ophthalmology segment but this year with Sanofi eyeing this therapeutic landscape we will have tough neck to neck competition between the two giants in Ophthalmology therapy landscape in the coming decade.

Read more in http://www.forexyard.com/en/news/Sanofi-RD-sets-sight-on-eye-diseases-2010-06-03T081726Z-INTERVIEW

Sanofi Aventis-Update

Last year in my blog I had mentioned something about Sanofi aventis penetration into emerging markets which include Latin American countries, India and China. For instance in Latin America it went into Merger and Acquisition of generic, India in similar way for acquisition of Shanta Biotech Hyderabad based Bio similar company and in China it went into to open its R&D centre for Biologics and generic production and now last week in a press release it was mentioned that Sanofi Aventis in going to invest around 5 Billion Yen in Japanese generic company Nichi- Iko Pharmaceutical.........now I guess next thing is that the company will try to strategize its marketing in South Asia.................. 

This week Update

Some 6-7 years back I had started working in the field of Molecular Biology and Fermentas and Geneart are the acronyms in our field.....This week there were following updates.............

- Life tech has purchased Germany based Gene-art for 47M USD, Gene-art has been into synthetic DNA, duplexes and oligos for a long time and with this acquisition Life tech has acquired capabilities from initial DNA synthesis to Bio-pharmaceutical pilot scale production.

- Thermo Fischer on the other hand into Biotechnology based instruments and storage and now it has acquired Fermentas (one of the market leaders in Restriction Digestion Technology, so now Novozyme and Danisco, New england Biolabs has touch competition ahead.

Now i am awaiting news from Qiagen as it has not done any major deals this quarter compared to last year 2009

Last week India Pharma Review

Till yesterday I was mad at finishing our final deliverable for a short term Client project and now as had a good 8 hrs sleep after long time so I am back to my old habit of doing my favourite thing……Writing my Blog………..Last week there was a major deal in the Indian subcontinent Abbott acquisition of Nicholas , earlier there were talks of GSK’s interest in acquiring Nicholas which never came through and GSk then went into getting stakes in Dr Reddy’s , Now I am awaiting one more million dollar deal in generic market in the Indian Subcontinent from Bristol Mayer Squibb, Merck and Pfizer ..As after this deal Abbott has got strong foothold in India and its time for Big daddies to gear up for next mega deal.

America's Most Popular drugs

Today after long time got a chance to write something for my Blog as there was a short term project going on and the file was delivered .....so now i am relaxing a bit ...............Last week and week end were quite hectic and now a days i am pursuing my passion for dance drama's .............Now about the pharma industry there were many small mergers and acquisitions in this fortnight but i am still waiting for the big players like Roche, BI, Bayer and Pfizer bigger M&A...........When i previewed the list and compared the Indian scenario i did not find a huge difference.

Today there was a update for America's Most Popular Drugs in IMS report. Following drugs are included in the list

Drug Name

Indication

Prescriptions 2009

Hydrocodone/ acetaminophen

Pain killer

128.2 M

Simvastatin

High cholesterol

83 M

Lisinopril

High Blood Pressure

81.3 M

Levothyroxine sodium

Thyroid disorders

66 M

Azithromycin

Antibiotics

53.8 M

Metformin

Diabetes

52 M

Lipitor

High cholesterol

51.5 M

Amlodipine

High blood pressure

50.9 M

Amoxicillin

Antibiotics

49.2 M

Hydrochlorothiazide

High Blood Pressure

47.1 M

Omeprazole

Heartburn

45.4 M

Alprazolam

Anxiety

44.4 M

Furosemide

High blood pressure

42.8 M

Metoprolol tartrate

Angina High blood pressure

40.5 M

Jaii Hooo

Yesterday Economic times headline "Dr Reddy's, Elder Pharma and Mankind Pharma to hire 3,000 people".....According to the sources

• Dr Reddy’s, Elder Pharma and Mankind Pharma each plan to hire 1,000 people in their marketing and sales force this year, Prabir Jha, global chief of HR at Dr Reddy’s, says the company had recruited 2,300 people last year.
• Lupin to add  800.
• GSK India had said it would hire about 300 people this year.......
• Novartis has also started hiring for its CI captive office in Hyderabad and Bristol Mayer Squibb for its Mumbai corporate office.

  According to the sources Indian local drug market is growing at over 17%. “So at even 15% growth, a Rs 10,000 crore market will be created next year...........